Lucjan Wyrwicz/LinkedIn
Jun 4, 2025, 10:22
Lucjan Wyrwicz: Sometimes a Single Study can change a lot in Oncology
Lucjan Wyrwicz, Head of Department, Dept. of Oncology and Radiotherapy at Maria Skłodowska-Curie Memorial Cancer Center, shared a post on LinkedIn:
“Sometimes a single study can change a lot in oncology. Matterhorn is an international study aimed to improve the outcomes in radical treatment of patients with the stomach cancer. Few extra infusions with minor side effects leads to major effect limiting greatly the chance of cancer recurrence. New agents are saving lives. Congratulations to Yelena Janjigian and the study team worldwide for this practice changing data. Great to be included as the co-author.
Btw: researchers from Maria Sklodowska-Curie National Research Institute of Oncology are included as co-authors in 3 of 5 abstracts presented at todays ASCO Presidential Session covering the most important and practice changing innovations shown during this years the most important oncology congress. Two thumbs up!”
Lucjan Wyrwicz highlighted the global impact of the Matterhorn trial, which demonstrates improved outcomes in radical stomach cancer treatment with minimal added toxicity. He also noted the involvement of his institution in several key ASCO 2025 presentations.
More posts featuring Lucjan Wyrwicz.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 4, 2025, 17:02
Jun 4, 2025, 16:33
Jun 4, 2025, 16:33
Jun 4, 2025, 15:56